Cbd

AHPA's McGuffin on DSHEA 2.0, CBD's path forward, and more

AHPA's McGuffin on DSHEA 2.0, CBD's path forward, and more

By Stephen Daniells

While AHPA supports H.R.841, the association wishes FDA “would do its job and establish a legal pathway [for hemp and CBD], but they haven’t,” said Michael McGuffin. “Something needs to happen.”

CRN’s Mister on the best solution for CBD, DSHEA 2.0, and more

CRN’s Mister on the best solution for CBD, DSHEA 2.0, and more

By Stephen Daniells

The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act represents ‘the best way’ to deal with the hemp-CBD issue for dietary supplements, says CRN’s Steve Mister, and once that’s clarified then the FDA and industry can address...

NPA’s Fabricant on CBD, NDI-related import alerts, and banned stimulants

NPA’s Fabricant on CBD, NDI-related import alerts, and banned stimulants

By Stephen Daniells

Efforts to move the needle on hemp-CBD at the Federal level are slow, and upcoming exits of key personnel at FDA are unlikely to affect progress much, says NPA’s Dr Daniel Fabricant. “In some ways I think FDA likes the status quo,” he tells NutraIngredients-USA.

getty | tinnakorn jorruang

CBD novel foods deadline delayed amid last minute applications

By Nikki Hancocks

The FSA (Food Standards Agency) has backtracked on its initial expectation for companies to make their novel foods applications at least five weeks in advance of the deadline and confirmed that it will accept applications up until March 31st, after receiving...

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers